Literature DB >> 12235528

Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli).

S Hongeng1, A Chuansumrit, P Hathirat, B Rerkamnuaychoke, W Chaisiripoomkere, S Jootar.   

Abstract

Bone marrow transplantation is the only therapeutic option that can eliminate thalassemic disease. Early results indicated that children in class 3 Lucarelli had a much worse outcome because of high nonrejection mortality and high rejection rate. We therefore tried to investigate a nonmyeloablative stem cell transplantation (NST) approach for such a disease in order to reduce mortality and rejection. We report here the case of successful NST in a 10-year-old girl who had class 3 Lucarelli beta-thalassemia major. The conditioning regimen consisted of busulfan, fludarabine, antilymphocyte globulin and total lymphoid irradiation. Her GVHD prophylaxis included mycophenolate mofetil and cyclosporin. The patient had full donor engraftment without acute and chronic GVHD. She is now alive and well and remains disease-free 1 year after transplant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235528     DOI: 10.1038/sj.bmt.1703655

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major.

Authors:  Yongliang Huo; Jonathan R Lockhart; Shanrun Liu; Suean Fontenard; Mike Berlett; Thomas M Ryan
Journal:  Blood Adv       Date:  2017-11-28

2.  Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.

Authors:  Rosarin Sruamsiri; Nathorn Chaiyakunapruk; Samart Pakakasama; Somtawin Sirireung; Nintita Sripaiboonkij; Udomsak Bunworasate; Suradej Hongeng
Journal:  BMC Health Serv Res       Date:  2013-02-05       Impact factor: 2.655

3.  Long--Term Free Survival of Two Class III β-Thalassemic Patients after Non-Myeloablative Stem Cell Transplantation.

Authors:  Mohammad Mahdi Adib Sereshki; Babak Bahar; Ardeshir Ghavamzadeh; Seyed Asadollah Mousavi; Kamran Alimoghaddam
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.